Education
About Us
Working with TipRanks
Follow Us
Inmode (DE:154)
NASDAQ:154
154 Stock Chart & Stats
€12.54
€0.39(2.41%)
At close: 4:00 PM EST
€12.54
€0.39(2.41%)
Day’s Range― - ―
52-Week Range€11.34 - €18.52
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€760.34M
Enterprise Value€616.72M
Total Cash (Recent Filing)€555.33M
Total Debt (Recent Filing)€13.23M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 04, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.39
Shares Outstanding63,358,750
10 Day Avg. Volume1
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.39
Price to Sales (P/S)2.56
P/FCF Ratio11.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.89Price Target Upside18.70% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consumables And Regional RecoveryAnalyst notes growth in consumables and record European revenues coupled with higher U.S. sales mix, indicating early signs of demand recovery in lower‑cost treatments and rising procedure volumes.
Product Pipeline And Recession-resistant FocusAnalyst highlights continued investment in noninvasive and wellness product launches and sales-force specialization, positioning the company in areas that tend to be more recession‑resistant and could support revenue stability.
Strategic Alternatives / Acquisition InterestAnalyst reports advanced acquisition talks and engagement of a bank to run a sales process that could attract bids paying meaningful premiums, potentially enhancing shareholder value.
Bears Say
Analyst Sentiment And Execution RiskAnalyst maintains a Hold rating due to inconsistent results and limited visibility into the aesthetic market recovery, noting the risk that a potential sale might not materialize and sustaining investor uncertainty.
Margin Pressure From Product MixAnalyst warns that planned launches shifting the product mix toward newer laser platforms are likely to reduce gross margins and lower adjusted earnings, putting pressure on profitability.
Market Demand And GuidanceAnalyst cautions that demand in North America remains below historical levels and company guidance implies essentially flat revenue, which could limit upside to sales.
InMode News
154 FAQ
What was Inmode’s price range in the past 12 months?
Inmode lowest stock price was €11.34 and its highest was €18.52 in the past 12 months.
What is Inmode’s market cap?
Inmode’s market cap is €760.34M.
When is Inmode’s upcoming earnings report date?
Inmode’s upcoming earnings report date is May 04, 2026 which is in 79 days.
How were Inmode’s earnings last quarter?
Inmode released its earnings results on Feb 10, 2026. The company reported €0.388 earnings per share for the quarter, beating the consensus estimate of €0.351 by €0.036.
Is Inmode overvalued?
According to Wall Street analysts Inmode’s price is currently Undervalued.
Does Inmode pay dividends?
Inmode does not currently pay dividends.
What is Inmode’s EPS estimate?
Inmode’s EPS estimate is 0.25.
How many shares outstanding does Inmode have?
Inmode has 63,358,750 shares outstanding.
What happened to Inmode’s price movement after its last earnings report?
Inmode reported an EPS of €0.388 in its last earnings report, beating expectations of €0.351. Following the earnings report the stock price went down -0.319%.
Which hedge fund is a major shareholder of Inmode?
Currently, no hedge funds are holding shares in DE:154
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InMode Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€14.89 (18.70% Upside)
€14.89 (18.70% Upside)
Blogger Sentiment
Bullish
DE:154 Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Bullish
Bullish news 79%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.35%
12-Months-Change
Fundamentals
Return on Equity
13.53%
Trailing 12-Months
Asset Growth
-2.45%
Trailing 12-Months
Company Description
Inmode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
154 Company Deck
154 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call contained a mix of encouraging operational and strategic developments (record international performance, rising consumables mix, new product launches, commercial reorganization, and a strong cash position with active buybacks) alongside clear financial headwinds (full-year revenue down ~6% YoY, margin compression, significant GAAP EPS declines, lower ASPs, and conservative 2026 guidance). Management frames 2026 as a stabilization year, emphasizing product pipeline and commercial improvements as levers for recovery; however, near-term profitability and top-line growth remain under pressure from product mix shifts, tariffs/import costs, and softer North American demand.View all DE:154 earnings summaries154 Stock 12 Month Forecast
Average Price Target
€14.89
▲(18.70% Upside)
Technical Analysis
Orthofix
―
AxoGen
―
Establishment Labs Holdings
―
SS Innovations International
―
Bioventus
―
Options Prices
Currently, No data available
---